3 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOPending
The main objective of this study is to investigate gender differences in P-gp function at the blood brain barrier, in order to gain further insight into the impact of these differences on the action of pharmaceuticals (antidepressants and…
Approved WMOPending
to assess the diagnostic accuracy of CSI (at 5, 10 and 15 cm proximal to the upper border of the lower esophageal sphincter) for the presence of active disease and/or complete remission in pediatric EoE.